AGITG TOP GEAR: A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer

AGITG TOP GEAR：可切除胃癌术前放化疗与术前化疗的随机 II/III 期试验

• 批准号: nhmrc : 2000711
• 金额: $ 62.16万
• 依托单位国家: 澳大利亚
• 项目类别: Clinical Trials and Cohort Studies Grants
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 2026-12-31
• 项目状态: 未结题
• 来源: https://researchdata.edu.au/agitg-top-gear-gastric-cancer/1780905
• 关键词: AGITG; TOP; GEAR; randomised; phase

While surgery to remove stomach cancer has been traditionally accepted as the only way to potentially cure the disease, there have been several recent advances using chemotherapy and/or radiotherapy both before and after surgery. Doctors' opinions remain divided regarding best treatments to give and in what order. This trial will address the important question of whether combined chemotherapy plus radiotherapy is more effective than chemotherapy alone in improving cure rates for stomach cancer.

虽然切除胃癌的手术传统上被认为是可能治愈该疾病的唯一方法，但最近在手术前和手术后使用化疗和/或放疗取得了一些进展。对于最佳治疗方法以及治疗顺序，医生们的意见仍然存在分歧。该试验将解决化疗加放疗联合化疗是否比单独化疗更有效地提高胃癌治愈率的重要问题。